Induction of ulcerative colitis in mice influences the course of infection with the nematode Trichuris muris

2014 ◽  
Vol 89 (5) ◽  
pp. 593-600 ◽  
Author(s):  
M.C. Vegas-Sánchez ◽  
E. Rollán-Landeras ◽  
J.J. García-Rodríguez ◽  
F. Bolás-Fernández

AbstractThe aim of this study was to assess the effect of infection with the nematode whipworm Trichuris muris on the course of chemically induced acute ulcerative colitis in CBA/J mice, a strain proven to be highly resistant to infection with T. muris. Each mouse was infected with 50 embryonated eggs of T. muris by oral gavage. Acute colitis was triggered by administering 4% dextran sulphate sodium (DSS) in the drinking water for nine consecutive days at different times after infection. Concurrent infection and DSS administration exacerbate the severity of the colitis while favouring the permanence of parasites in the intestine. The induction of ulcerative colitis from days 54 to 62 post-infection (p.i.), when all worms had been expelled, ameliorated the course of the inflammatory disease. When ulcerative colitis was triggered earlier on, from days 27 to 35 p.i., the beneficial effects on inflammatory events were clearly shown with signs of mucosal epithelization and regeneration as early as day 1 after DSS administration. Previous infections by T. muris therefore accelerate recovery from subsequently induced inflammatory bowel disease and such an effect assists the nematode to persist in the intestinal niche.

2019 ◽  
Vol 855 ◽  
pp. 192-201 ◽  
Author(s):  
Sateesh Alavala ◽  
Rajendra Sangaraju ◽  
Nasiruddin Nalban ◽  
Bidya Dhar Sahu ◽  
Mahesh Kumar Jerald ◽  
...  

2014 ◽  
Vol 2 (3) ◽  
pp. 103-104
Author(s):  
A. Somasundaram ◽  
A.T. Rajarajan ◽  
P. Vigneshwaran ◽  
K. Vengadeshprabhu ◽  
H. Meilei ◽  
...  

2020 ◽  
Vol 64 ◽  
pp. 103602 ◽  
Author(s):  
Qian Zhou ◽  
Lei Ma ◽  
Wenyang Zhao ◽  
Wen Zhao ◽  
Xue Han ◽  
...  

2020 ◽  
Vol 15 (3) ◽  
pp. 174-182 ◽  
Author(s):  
Marianna Roselli ◽  
Alberto Finamore

Inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, are currently considered multifactorial pathologies in which various combined environmental factors act on genetic background, giving rise to chronic inflammation of the gastrointestinal tract. Ulcerative colitis is an inflammation of the colon caused by a dysregulated immune response to host intestinal microbiota in genetically susceptible subjects. Ulcerative colitis has a strong impact on patients' quality of life, as well as high costs for the health-care system. A great interest on the role of intestinal microbiota modulation in ulcerative colitis is emerging. Several studies have shown an improvement of inflammatory markers and symptoms in ulcerative colitis patients through treatments with probiotics and prebiotics separately. Despite the low number of studies on the treatment of ulcerative colitis by specific strains of probiotics plus selected prebiotics, i.e. synbiotics, the results are promising, even if discordant. The mechanism of action in synbiotics supplementation is still unclear and needs more investigation, although there is a large number of data indicating that the synergism between probiotics and prebiotics favours the survival and implantation of probiotics into the gastrointestinal tract with beneficial effects on human health by modulating the inflammatory response and gut microbiota composition. The aim of this minireview is to describe the main in vitro, animal and human studies performed up to now, that have used synbiotics to treat ulcerative colitis, and to highlight limitations and future perspectives.


2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Qingdong Guan ◽  
Jiguo Zhang

Cytokines play an important role in the immunopathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, where they drive and regulate multiple aspects of intestinal inflammation. The imbalance between proinflammatory and anti-inflammatory cytokines that occurs in IBD results in disease progression and tissue damage and limits the resolution of inflammation. Targeting cytokines have been novel strategies in the treatment of IBD. Recent studies show the beneficial effects of anticytokine treatments to IBD patients, and multiple novel cytokines are found to be involved in the pathogenesis of IBD. In this review, we will discuss the recent advances of novel biologics in clinics and clinical trials, and novel proinflammatory and anti-inflammatory cytokines found in IBD with focusing on IL-12 family and IL-1 family members as well as their relevance to the potential therapy of IBD.


2017 ◽  
Vol 18 (3) ◽  
pp. 213-220
Author(s):  
Bojana Simovic Markovic ◽  
Neda Milosavljevic ◽  
Aleksandar Arsenijevic ◽  
Marina Gazdic ◽  
Miodrag L. Lukic ◽  
...  

AbstractAn altered immune response to normal gut microflora is important for the pathogenesis of ulcerative colitis (UC). Galectin- 3 (Gal-3) is an endogenous lectin that plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of the NLRP3 infl ammasome and production of IL-1β in macrophages. By using dextran sulphate sodium (DSS) induced colitis, a well-established animal model of UC, we determined whether Gal-3 affects the function of colon infiltrating macrophages by interfering with intestinal microfl ora. Our results showed that genetic deletion of Gal-3 significantly attenuates DSS-induced colitis by down-regulating infiltration of phagocytic cells (neutrophils, macrophages and dendritic cells) in colon tissue of DSS-treated mice, and this correlated with differences in bacterial flora of the gut. Antibiotic treatment attenuates DSS-induced colitis in WT and Gal-3-/- mice without affecting differences between the groups. In conclusion, Gram negative bacterial flora play an important role in DSS-induced acute colitis of mice but are not involved in Gal-3 dependent modulation of colon inflammation.


2021 ◽  
Author(s):  
Nava Morshedzadeh ◽  
Mehran Rahimlou ◽  
Shabnam Shahrokh ◽  
Soheila Karimi ◽  
Vahid Chaleshi ◽  
...  

Abstract Introduction: Inflammatory bowel disease (IBD) is one of the most common gastrointestinal diseases that can affect people of all ages. Adipokines secreted from adipose tissue have been shown to play an important role in the pathogenesis of ulcerative colitis (UC). The aim of this study was to evaluate the effect of supplementation with your seed on the concentrations of adiponectin, resistin and visfatin in patients with UC.Methods: This trial is an open-labeled randomized controlled trial which conducted among 70 patients with UC. Patients were randomly divided into two groups: flaxseed and control. Patients in the intervention were received 30 g/day flaxseed powder for 12 weeks. Anthropometric, nutritional and biochemical factors of patients were evaluated at the beginning and end of the intervention period.Results: Totally, 64 patients (36 men and 28 women) with mean age of 31.12 ± 9.67 included in the final analysis. There wasn’t any significant difference between two groups in term of baseline weight and height (P>0.05). After the 12 weeks' intervention, flaxseed supplementation led to a significant reduction in the resistin (-4.85 ± 1.89 vs. -1.10 ± 2.25, P<0.001) and visfatin concentration (-1.33± 1.14 vs. -0.53 ± 1.63, P=0.018). Moreover, we found a significant increase in the adiponectin levels after the flaxseed supplementation (3.49 ± 1.29 vs. -0.35 ± 0.96, P<0.001).Conclusion: It has been reported in this study that flaxseed supplementation could exert beneficial effects on adipokine levels in patients with UC. Trial registration: IRCT registration no. IRCT20180311039043N1


Sign in / Sign up

Export Citation Format

Share Document